Cargando…
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes comp...
Autores principales: | Colca, J R, VanderLugt, J T, Adams, W J, Shashlo, A, McDonald, W G, Liang, J, Zhou, R, Orloff, D G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604641/ https://www.ncbi.nlm.nih.gov/pubmed/23462886 http://dx.doi.org/10.1038/clpt.2013.10 |
Ejemplares similares
-
An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease
por: Shah, Raj C, et al.
Publicado: (2014) -
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
por: Colca, Jerry R., et al.
Publicado: (2013) -
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide
por: Kamm, Dakota R., et al.
Publicado: (2021) -
Optical signal processing
por: VanderLugt, Anthony
Publicado: (2005) -
Magnetic measurements of the steel septum magnet used for extraction: MSDC01
por: Cornuet, D, et al.
Publicado: (2002)